(Press-News.org) A blood-borne molecule that increases in abundance as we age blocks regeneration of brain cells and promotes cognitive decline, suggests a new study by researchers at UC San Francisco and Stanford School of Medicine.
The molecule in question, known as beta-2 microglobulin, or B2M, is a component of a larger molecule called MHC I (major histocompatibility complex class I), which plays a major role in the adaptive immune system. A growing body of research indicates that the B2M-MHC I complex, which is present in all cells in the body except red blood cells and plasma cells, can act in the brain in ways not obviously related to immunity--guiding brain development, shaping nerve cell communication, and even affecting behavior.
"We are in the process of elucidating the exact mechanism by which B2M works," said Saul A. Villeda, PhD, a UCSF Faculty Fellow and co-senior author of the new study. "Since B2M increases with age, both in the blood and in the brain, we want to know what is the 'traditional' immune contribution to effects on cognition, and what is the non-traditional neural contribution."
In 2014, highly publicized work in the laboratories of Villeda and Tony Wyss-Coray, PhD, professor of neurology at Stanford, showed that connecting the circulatory system of a young mouse to that of an old mouse could reverse the declines in learning ability that typically emerge as mice age.
Over the course of their long-term research on so-called young blood, however, the researchers had noted an opposite effect: blood from older animals appears to contain "pro-aging factors" that suppress neurogenesis--the sprouting of new brain cells in regions important for memory--which in turn can contribute to cognitive decline.
In the new research, published online on July 6, 2015 in Nature Medicine, Villeda and co-senior author Wyss-Coray again joined forces to follow up on these findings, as well as a range of studies correlating high B2M blood levels with cognitive dysfunction in Alzheimer's disease, HIV-associated dementia, and as a consequence of chronic dialysis for kidney disease.
Members of the Villeda and Wyss-Coray labs first showed that B2M levels steadily rise with age in mice, and are also higher in young mice in which the circulatory system is joined to that of an older mouse. These findings were confirmed in humans, in whom B2M levels rose with age in both blood and in the cerebrospinal fluid (CSF) that bathes the brain.
When B2M was administered to young mice, either via the circulatory system or directly into the brain, the mice performed poorly on tests of learning and memory compared to untreated mice, and neurogenesis was also suppressed in these mice.
These experiments were complemented by genetic manipulations in which some mice were engineered to lack a gene known as Tap1, which is crucial for the MHC I complex to make its way to the cell surface. In these mice, administration of B2M in young mice had no significant effect, either in tests of learning or in assessments of neurogenesis.
The group also bred mice missing the gene for B2M itself. These mice performed better than their normal counterparts on learning tests well into old age, and their brains did not exhibit the decline in neurogenesis typically seen in aged mice.
Villeda emphasized that the effects on learning observed in the B2M-administration experiments were reversible: 30 days after the B2M injections, the treated mice performed as well on tests as untreated mice, indicating that B2M-induced cognitive decline in humans could potentially be treated with targeted drugs.
"From a translational perspective, we are interested in developing antibodies or small molecules to target this protein late in life," said Villeda. "Since B2M goes up with age in blood, CSF, and also in the brain itself, this allows us multiple avenues in which to target this protein therapeutically."
INFORMATION:
First authors of the new study are graduate student Lucas K. Smith and Research Associate Cedric E. Snethlage, both at UCSF; former Stanford postdoctoral fellow Yingbo He, PhD, now a scientist at Johnson & Johnson; Jeong-Soo Park, PhD, of Dankook University College of Medicine, in Korea; and Stanford graduate student Gregor Bieri.
Funders of the work include the California Institute for Regenerative Medicine; the National Science Foundation; the Department of Veterans Affairs; the National Institute on Aging; the Sandler Foundation; Marc and Lynne Benioff; the UCSF Clinical and Translational Science Institute; and the National Institutes of Health.
What gives plastic objects their flexibility and reduces their brittleness is the concentration of plasticiser. For example, a chemical solvent of the phthalate family called DOP is often used. The trouble is there are concerns that phthalates present health risks. So there is a demand for more alternatives. Now, scientists from China have examined the effect of using DEHHP, a new eco-friendly plasticiser, used in combination with PVC. For a plasticiser to work, there has to be adequate hydrogen bonding with the plastic. By combining experiments and simulations, the team ...
Nearly 800 million people worldwide don't have access to safe drinking water, and some 2.5 billion people live in precariously unsanitary conditions, according to the Centers for Disease Control and Prevention. Together, unsafe drinking water and the inadequate supply of water for hygiene purposes contribute to almost 90% of all deaths from diarrheal diseases -- and effective water sanitation interventions are still challenging scientists and engineers.
A new study published in Nature Nanotechnology proposes a novel nanotechnology-based strategy to improve water filtration. ...
Optogenetics techniques, which allow scientists to map and control nerve cells using light stimulation, are being used to study neural circuits in the brain with unprecedented precision. This revolutionary technology relies on light-sensitive proteins such as channelrhodopsins, and researchers at UC Santa Cruz have now determined the molecular mechanism involved in the light-induced activation of one of these proteins.
The new findings, published July 3 in two papers in the Journal of Biological Chemistry, can help scientists create tailor-made proteins optimized for ...
Evolutionary change in a gene resurrected in the lab from the extinct woolly mammoth altered the gene's temperature sensitivity and likely was part of a suite of adaptations that allowed the mammoth to survive in harsh arctic environments, according to new research. In a study published in Cell Reports on July 2, 2015, researchers determined the whole-genome sequence of two woolly mammoths and three modern Asian elephants, predicted the function of genetic changes found only in the mammoths, and then experimentally validated the function of a woolly mammoth gene reconstructed ...
An international team, led by a University of Adelaide genetics expert, has made a breakthrough discovery which is expected to help thousands of young girls worldwide who are suffering from a rare yet debilitating form of epilepsy.
Professor Jozef Gecz, from the University of Adelaide's Robinson Research Institute, was a key player in identifying the responsible gene and mutations in this female-only epileptic syndrome, in 2008.
In breakthrough research published in Oxford Journals, Human Molecular Genetics, Professor Gecz has now found a treatment for this disorder. ...
(PHILADELPHIA) -- Transfer RNAs (tRNAs) are ancient molecules and indispensable components of all living cells - they are found in all three kingdoms of life i.e., in archaea, bacteria and eukaryotes. In a cell, they are part of the machinery that translates messenger RNA (mRNA) sequences into amino acid sequences.
In recent years advances in sequencing technology have enabled detailed investigations of the RNA molecules that are active in a cell. A study published July 6th in the journal Oncotarget reports on a newly discovered category of tRNA fragments as well as ...
Andrew Hicks from the Museum of Natural History at the University of Colorado and his team discovered a previously unknown leafhopper species in the New Jersey Pine Barrens, located just east of the megalopolis that extends from New York City to Washington, DC. This was the first time an insect has been reported from the state-listed threatened pinebarren smokegrass, Muhlenbergia torreyana. The study can be found in the open-access journal ZooKeys.
The discovery was made with the help of Dr. Gerry Moore of the Natural Resources Conservation Service in Greensboro, NC, ...
Young children, who possess a good understanding of their own emotions and of those of their fellow human beings early on, suffer fewer attention problems than their peers with a lower emotional understanding. Evidence of this phenomenon was found through a study of Leuphana University of Lueneburg and George Mason University, USA, under the auspices of Prof. Dr. Maria von Salisch, Professor of Developmental Psychology at Leuphana University of Lueneburg. The study was recently published in the journal Kindheit & Entwicklung (Childhood & Development).
The findings stem ...
Results of EORTC trial 62072 appearing in Cancer show that in patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life. This observed improvement in progression-free survival without impairment of health-related quality of life was considered a meaningful result.
There has not been a lot of research that has looked into the quality of life of patients with advanced soft tissue sarcoma. The results of this EORTC health related quality ...
The risk of experiencing another stroke is higher if patients, after dilation of their blood vessels in the brain, receive not only clot-inhibiting drugs, but also have stents inserted. The recently published results of the VISSIT study confirm this conclusion of a rapid report by the German Institute for Quality and Efficiency in Health Care (IQWiG) of October 2014. Thus, the available studies still provide no evidence of a benefit of treatment with intracranial stents (also called "percutaneous transluminal angioplasty and stenting", PTAS). This is the conclusion of a ...
